THU0626 Cost-effectiveness of early treatment of acpa positive rheumatoid arthritis patients with abatacept

Abstract

BackgroundStudies have reported that the presence of elevated anti-citrullinated protein antibodies (ACPA)/RF levels, together with joint erosions, is associated with higher disease burden in terms of disability, and mortality in rheumatoid arthritis (RA). Abatacept has been shown to be effective in this patient population with favorable comparative data against adalimumab.(1) However, few studies have investigated the cost effectiveness of abatacept in this population to similar treatments such as TNFs.ObjectivesThe objective of the study was to compare the cost-effectiveness of abatacept to adalimumab as a first bDMARD in ACPA positive RA patients who failed treatment with methotrexate (MTX) in Germany.MethodsA decision tree model was used to estimate the cost-effectiveness, from a payer's perspective, of different treatment sequences in RA over a two year time frame. The effectiveness criteria were defined as achieving the treatment target measured by the Disease Activity Score 28 (DAS28 (CRP)<2.6; “remission”). A treatment switch to a different biologic as 2nd line and 3rd line bDMARD was allowed -in case of not achieving remission with therapy- every 6 months over a two year time period. Effectiveness data was based on randomized controlled trials (RCT) identified by an updated previous systematic literature search by the Institute for Quality and Efficiency in Health Care (IQWiG). Costs of medication and other direct medical costs were taken from a recent publication (2) and included in the analysis. Cost-effectiveness of RA treatment was investigated in ACPA positive patients in this study and presented as overall costs per day in remission. To manage uncertainty in the model, a fully probabilistic approach was used with 10,000 runs.ResultsFor ACPA positive patients, treatment strategies including early treatment with abatacept had lower total costs per clinical outcome compared to later use. Figure 1 summarizes the costs per day in remission for the treatment sequences investigated: treatment sequences starting with abatacept resulted in lower costs for reaching remission (mean 330 €/day, range 328 €-333 €/day) compared to sequences starting with adalimumab (mean 384 €/day, range 378 €-390 €/day). Choice of the second or third biologic in the treatment sequences appears to have little impact on the costs per outcome.ConclusionsThe results of this analysis suggest that in ACPA positive RA patients treatment with abatacept appears to be more cost-effective compared to treatment with adalimumab as a first bDMARD.References Sokolove J, Schiff M, Fleischmann R, et al. Annals of the rheumatic diseases. 2016 Apr;75(4):709–14.Beresniak A, Baerwald C, Zeidler H et al. Clin Exp Rheumatol. 2013 May-Jun;31(3):400–8. Disclosure of InterestA. Neubauer Grant/research support from: BMS, Intercept, Roche, Santen, C. Minartz Grant/research support from: BMS, Intercept, Roche, K. Herrmann Employee of: BMS, R. Postema Employee of: BMS, C. Baerwald Grant/research support from: Abbvie, Biogen, BMS, Chugai, Hexal, Medac, Pfizer,...

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis

“…The findings from our analysis are consistent with such a model in which an early 'window of opportunity' exists to achieve the best outcomes. Moreover, the use of abatacept as a first-line bDMARD following an inadequate response to MTX has been shown to be more cost-effective than the use of adalimumab at this stage, in anti-citrullinated protein antibody-positive patients with RA [9].…”

Early diagnosis and treatment of rheumatoid arthritis

“…Therefore, they found that 99mTc-3PRGD2 is a promising agent for the early diagnosis of rheumatoid arthritis. The study was conducted in Germany [4] . The results of the study suggests that an early treatment of patients with abatacept has advantages compared to adalimumab for both the patients and the payers and treatment with abatacept appears to have lower costs per response (remission) compared to treatment with adalimumab as a first bDMARD.…”

A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis

“…This study included costs for drugs, concomitant drugs, disease monitoring, and adverse events. Another study developed a decision tree model to compare the cost-effectiveness of abatacept to adalimumab over 2 years in Germany among the same target population as the previous cost per responder/remission study 34 . The model allowed switching to second-line and third-line of biologic therapy for patients who do not respond to the first line abatacept or adalimumab.…”